Patent ID: 11938192
Assignee: MEDIMMUNE LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 10:
11. A method of treating a subject suffering from a proliferative disease, said method comprising:
administering to a subject suffering from a proliferative disease an effective amount of a CD19-antibody drug conjugate (ADC),
wherein the CD19-ADC has the chemical structure:, and the Ab is a CD19 antibody comprising a VH domain having the amino acid sequence of SEQ ID NO.2 and a VL domain having the amino acid sequence of SEQ ID NO. 8, and the drug to antibody ratio (DAR) is between 1 and 8;
wherein (i) the CD19-ADC is administered to the subject in a dosage regime comprising at least two treatment cycles; and (ii) the dose of CD19-ADC is reduced following the second treatment cycle; and
wherein the proliferative disease is CD19+.